Bitcoin Cash halving has no impact on price action

Bitcoin Cash halving has no impact on price action

With the Bitcoin halving being just one month away you could forgive people for forgetting about Bitcoin Cash and its own block reward halving, which actually happened today. Miners will now receive 6.25 BCH per block as opposed to 12.5 BCH per block, which theoretically means the price would need to double for mining to remain as profitable. However, Bitcoin Cash is now 5.68% down over the past four hours despite block rewards being slashed, leaving a sour taste in mouths of investors. The difference between the Bitcoin halving in May and the Bitcoin Cash halving is that miners are more inclined to mine Bitcoin due to its value being $7,250 compared to Bitcoin Cash, which is worth just $263....

GM to supply 30,000 ventilators in $500 million U.S. contract

The Department of Health and Human Services contract is the first for ventilator production under the Defense Production Act, invoked by President Donald Trump to get companies to produce essential gear needed to fight the pandemic. GM will work with ventilator firm Ventec Life Systems to deliver 30,000 ventilators under the contract to the U.S. government by the end of August, with deliveries of the first 6,132 ventilators taking place by June 1....

Moleculin Biotech Doubles In Pre-Market Trading On Potential Covid-19 Treatment

Moleculin Biotech (MBRX) today announced that 2-deoxy-D-glucose (“2-DG”) reduced the virus that causes COVID-19 by 100% in in vitro testing, according to independent research. On the news shares surged 155% in pre-market trading from $0.56 to $0.85.Researchers at the University of Frankfurt disclosed the findings in their article submitted to NatureResearch on March 11, 2020. The authors of the research reported that inhibiting glycolysis with non-toxic concentrations of 2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells.Moleculin’s drug candidate, WP1122, is referred to as a “prodrug” of 2-DG as chemical elements are added to 2-DG to improve its delivery in vivo.“This is the breakthrough we were looking for, only it came from an unexpected source,” commented Walter Klemp, CEO of Moleculin. “Normally, we wouldn’t have access to data like this until it is published, but the willingness of the authors to pre-release this data will help support our development of WP1122 for treating...